The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
August 22nd 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 22, 2025.
Novel Radiotracer May Serve as Valuable Diagnostic Biomarker For Supranuclear Palsy
July 15th 2020The 18F-PI-2620 radiotracer’s positive effect on diagnosing and differentiating patients with suspected progressive supranuclear palsy leaves questions about its potential as a PSP progression biomarker.
Daniel Claassen, MD, MS: Selective Knock-Downs in Huntington Disease
July 8th 2020The associate professor of neurology at Vanderbilt University Medical Center spoke to the findings of a recent study in Huntington disease that assessed the feasibility of selectively knocking down mutant protein expression.
Baseline Dyskinesia Linked to Adverse Event Dyskinesia While on Istradefylline
June 4th 2020Post-hoc data presented at the EAN Congress suggest patients with dyskinesia prior to starting treatment on the Kyowa Kirin agent were more likely to experience dyskinesia as an adverse event during treatment.
The Advantages of Independent Contact-Current Controlled DBS Devices
June 3rd 2020The professor and head of the department of neurology at the University of Minnesota spoke to the recent findings of a study of Boston Scientific's multiple independent contact current-controlled device for deep brain stimulation.
Jerrold L. Vitek, MD, PhD: Multiple Independent Contact Current-Controlled DBS Technology
June 1st 2020The professor and head of the department of neurology at the University of Minnesota discussed what multiple independent contact current-controlled devices offer physicians conducting deep brain stimulation.
Vercise DBS System Shows Safety and Efficacy in Treating Parkinson Motor Symptoms
May 31st 2020From post-implantation screening to 3 months, those in the active treatment arm reported a mean improvement of 3.03 more hours of on time than the control group with Boston Scientific’s deep brain stimulation device.